MSD Partners’s Alaunos Therapeutics TCRT Stock Holding History

MSD Partners’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-101,010	Closed	-$325K	–	16
2024 Q3	$325K	Hold	101,010	–	–	0.21%	12
2024 Q2	$706K	Hold	101,010	–	–	0.07%	12
2024 Q1	$1.83M	Hold	101,010	–	–	0.15%	12
2023 Q4	$1.07M	Hold	101,010	–	–	0.09%	14
2023 Q3	$2M	Hold	101,010	–	–	0.16%	21
2023 Q2	$7.73M	Hold	101,010	–	–	0.71%	6
2023 Q1	$9.55M	Hold	101,010	–	–	0.78%	7
2022 Q4	$9.83M	Hold	101,010	–	–	0.97%	7
2022 Q3	$26.1M	Hold	101,010	–	–	2.11%	5
2022 Q2	$18.8M	Hold	101,010	–	–	1.16%	5
2022 Q1	$9.88M	Sell	101,010 -202,020	-67%	-$25.9M	0.54%	12
2021 Q4	$49.5M	Buy	303,030 +202,020	+200%	+$44.4M	0.54%	19
2021 Q3	$27.6M	Hold	101,010	–	–	0.84%	19
2021 Q2	$40M	Hold	101,010	–	–	1.04%	14
2021 Q1	$54.5M	Hold	101,010	–	–	2.07%	4
2020 Q4	$38.2M	Hold	101,010	–	–	6.38%	3
2020 Q3	$38.2M	Hold	101,010	–	–	7.99%	3
2020 Q2	$49.7M	Hold	101,010	–	–	12.67%	2
2020 Q1	$37.1M	Hold	101,010	–	–	10.04%	2
2019 Q4	$71.5M	Hold	101,010	–	–	15.74%	2
2019 Q3	$64.8M	Buy	101,010 +27,768	+38%	+$22M	8.7%	4
2019 Q2	$64M	Hold	73,242	–	–	7.77%	3
2019 Q1	$42.3M	Hold	73,242	–	–	5.23%	8
2018 Q4	$20.5M	Buy	73,242 +50,505	+222%	+$20M	1.79%	8
2018 Q3	$10.9M	Hold	22,737	–	–	0.82%	25
2018 Q2	$10.3M	Hold	22,737	–	–	0.44%	21
2018 Q1	$13.4M	Hold	22,737	–	–	0.68%	15
2017 Q4	$14.1M	Hold	22,737	–	–	0.73%	11
2017 Q3	$20.9M	Hold	22,737	–	–	0.61%	16
2017 Q2	$21.2M	Hold	22,737	–	–	1.32%	17
2017 Q1	$21.6M	Hold	22,737	–	–	1.08%	16
2016 Q4	$18.2M	Hold	22,737	–	–	0.92%	16
2016 Q3	$19.2M	Hold	22,737	–	–	1.55%	14
2016 Q2	$18.7M	Sell	22,737 -986	-4%	-$1.07M	1.22%	20
2016 Q1	$26.4M	Sell	23,723 -3,334	-12%	-$3.41M	1.38%	12
2015 Q4	$33.7M	Sell	27,057 -2,333	-8%	-$3.86M	1.43%	16
2015 Q3	$39.7M	Sell	29,390 -443	-1%	-$731K	1.31%	22
2015 Q2	$53.7M	Buy	29,833 +333	+1%	+$517K	1.08%	21
2015 Q1	$47.7M	Buy	29,500 +2,036	+7%	+$3.02M	1.13%	23
2014 Q4	$20.9M	Buy	27,464 +9,131	+50%	+$4.85M	0.49%	35
2014 Q3	$7.26M	Hold	18,333	–	–	0.22%	45
2014 Q2	$11.1M	Hold	18,333	–	–	0.29%	45
2014 Q1	$12.6M	Hold	18,333	–	–	0.48%	42
2013 Q4	$11.9M	Buy	18,333 +10,666	+139%	+$6.35M	0.49%	45
2013 Q3	$4.53M	Hold	7,667	–	–	0.17%	48
2013 Q2	$2.43M	Buy	+7,667	New	+$2.13M	0.13%	42

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

MSD Partners's TCRT Position: Q4 2024 in Review

MSD Partners sold out of Alaunos Therapeutics (TCRT) in Q4 2024, closing a stake of 101,010 shares — an estimated $325K sold.

MSD Partners first reported a position in TCRT in Q2 2013 and held it in 46 quarters. The position peaked at $71.5M in Q4 2019. 30 funds tracked by Wall St. Rank hold TCRT as of Q4 2024.

MSD Partners reported no remaining Alaunos Therapeutics position as of Q4 2024 after selling out during the quarter.
MSD Partners sold 101,010 Alaunos Therapeutics shares in Q4 2024, an estimated $325K.
MSD Partners first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 46 quarters.
MSD Partners's Alaunos Therapeutics position peaked at $71.5M in Q4 2019.
30 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2024.

Based on MSD Partners's 13F filing for Q4 2024, filed 14 Feb 2025.